BlueBrainBoost
freedom-pharmacy
Purchases through the above links give commission which helps fund this website
Recent literature: Dipeptidyl peptidase 4 inhibitor
Date Journal Article title
2019 Apr Cochrane Database Syst Rev Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.
2019 Apr Diabetes Obes Metab Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomised controlled study (PRIME-V study).
2019 Apr Lancet Diabetes Endocrinol Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
2019 Apr Drugs The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.
2019 Feb Kidney Int Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 56 nephrectomy.
2019 Apr Clin Exp Hypertens Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T).
2019 Apr Br J Clin Pharmacol DPP-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
2019 Apr Circulation Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study.
2019 Apr Diabetes Res Clin Pract Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
2019 Artif Cells Nanomed Biote... The protective effects of saxagliptin against lipopolysaccharide (LPS)-induced inflammation and damage in human dental pulp cells.
2019 Apr Diabetes Obes Metab Cardiovascular safety of linagliptin compared to other oral glucose lowering agents in patients with type 2 diabetes: a sequential monitoring program in routine care.
2019 Apr Pharmazie The dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates renal injury in type 1 diabetic mice iviai inhibiting the TGF-βSmad signal pathway.
2019 Mar Diabetes Ther Acquired Hemophilia A Associated with Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus: A Single-Center Case Series in Japan.
2019 Feb Acta Histochem Cytochem Immunohistochemistry for Anti-diabetes Drug, Alogliptin Using a Newly Prepared Monoclonal Antibody: Its Precise Localization in Rat Small Intestine.
2019 Mar EBioMedicine Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis.
2019 Endocrinol Metab (Seoul) Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea.
2019 Mar Diabetes Res Clin Pract Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study.
2019 Mar Sci Rep Development of a 13C Stable Isotope Assay for Dipeptidyl Peptidase-4 Enzyme Activity A New Breath Test for Dipeptidyl Peptidase Activity.
2019 Mar Diabetes Care The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
2019 Apr J Agric Food Chem A Supramolecular Approach to Develop New Soybean and Lupin Peptide Nanogels with Enhanced Dipeptidyl Peptidase IV (DPP-IV) Inhibitory Activity.
2019 Feb Diabetes Metab J Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study.
2019 Mar BMC Cardiovasc Disord Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
2019 Mar Int J Mol Sci Discovery of Galangin as a Potential DPP-4 Inhibitor That Improves Insulin-Stimulated Skeletal Muscle Glucose Uptake: A Combinational Therapy for Diabetes.
2019 Mar Clin Exp Dermatol Exacerbation of well-controlled bullous pemphigoid by the administration of a dipeptidyl peptidase-4 inhibitor.
2019 Front Pharmacol Vildagliptin Reduces Stenosis of Injured Carotid Artery in Diabetic Mouse Through Inhibiting Vascular Smooth Muscle Cell Proliferation via ER StressNF-κB Pathway.
2019 Mar Cardiovasc Diabetol Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
2019 Mar BMC Pharmacol Toxicol Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis.
2019 Mar Diabetes Obes Metab Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017.
2019 Aliment Pharmacol Ther Randomised clinical trial: the DPP-4 inhibitor, vildagliptin, inhibits gastric accommodation and increases glucagon-like peptide-1 plasma levels in healthy volunteers.
2019 Mar BMJ Open Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study.
2019 Mar BMC Nephrol DPP-4 inhibition enhanced renal tubular and myocardial GLP-1 receptor expression decreased in CKD with myocardial infarction.
2019 Feb Cardiovasc Diabetol Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials.
2019 Feb Int J Clin Pract Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
2019 Diabetol Int Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study.
2019 Ther Adv Endocrinol Metab Diabetes: the place of new therapies.
2019 Pharmacology Design and Discovery of Novel 1,3,5-Triazines as Dipeptidyl Peptidase-4 Inhibitor against Diabetes.
2019 Apr Biochem Biophys Res Commun Alogliptin alleviates liver fibrosis via pression of activated hepatic stellate cell.
2019 Feb Diabetes Res Clin Pract Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure.
2018 Methodist Debakey Cardiov... New Therapeutic Strategies for Type 2 Diabetes CME.
2019 May Eur J Pharmacol The effect of exenatide (a GLP-1 analog) and sitagliptin (a DPP-4 inhibitor) on plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and concentration in normal and fructose-fed rats.
2019 Feb Am J Cardiovasc Drugs Cardiovascular Protection with Anti-hyperglycemic Agents.
2019 Feb Heart Vessels Liraglutide presses atrial electrophysiological changes.
2019 PLoS One Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study.
2019 Mar Int Heart J Linagliptin Suppresses Electrical and Structural Remodeling in the Isoproterenol Induced Myocardial Injury Model.
2019 PLoS One Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study.
2019 Endocr Pract CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
2019 Int J Cardiol Heart Vasc The effect of DPP-4-protected GLP-1 (7-36) on coronary microvascular function in obese adults.
2019 Pharmacoepidemiol Drug Saf Use of dipeptidyl peptidase-4 inhibitors and the risk of arthralgia: Population-based cohort and nested case-control studies.
2019 Feb Diabetes Obes Metab Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications.
2019 Feb Drug Dev Res Protective role of sitagliptin against oxidative stress in a kainic acid-induced status epilepticus in rats models via Nrf2HO-1 pathway.
2019 Jan Prim Care Diabetes Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
2019 Clin Ther Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
2019 Inflammation DPP-4 Inhibition Leads to Decreased Pancreatic Inflammatory Profile and Increased Frequency of Regulatory T Cells in Experimental Type 1 Diabetes.
2019 J Clin Med Res Investigation of a Dipeptidyl Peptidase-4 InhibitorThiazolidinedione Combination Drug for Patients With Type 2 Diabetes and Poor Glycemic Control: Difficulty With Patient Enrollment.
2019 Jan Ann Pharmacother Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis.
2019 Nephron Amelioration of Early Markers of Diabetic Nephropathy by Linagliptin in Fructose-Streptozotocin-Induced Type 2 Diabetic Rats.
2019 Jan Carcinogenesis The CD26DPP4-inhibitor vildagliptin presses lung cancer growth via macrophage-mediated NK cell activity.
2019 Diabetes Obes Metab Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers.
2019 Jan Endocr Connect Incretin-based therapies for patients with type 1 diabetes: a meta-analysis.
2019 Mar J Med Chem Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes.
2019 Diabetes Ther Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis.
2019 Diabetes Metab J Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors.
2019 Jan J Pain Palliat Care Pharm... The Association of Joint Pain and Dipeptidyl Peptidase-4 Inhibitor Use Among U.S. Adults With Type-2 Diabetes Mellitus.
2019 Jan Br J Dermatol Epitope-spreading phenomena in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
2019 Jan J Health Popul Nutr Comparison of biochemical parameters among DPP4 inhibitor users and other oral hypoglycaemic drug users: a cross-sectional study from Anuradhapura, Sri Lanka.
2019 Yonsei Med J Signal Detection for Cardiovascular Adverse Events of DPP-4 Inhibitors Using the Korea Adverse Event Reporting System Database, 2008-2016.
2019 Mol Immunol Anagliptin ameliorates high glucose- induced endothelial dysfunction via pression of NLRP3 inflammasome activation mediated by SIRT1.
2019 Jan Int J Mol Sci A Novel Dipeptidyl Peptidase IV Inhibitory Tea Peptide Improves Pancreatic β-Cell Function and Reduces α-Cell Proliferation in Streptozotocin-Induced Diabetic Mice.
2019 Feb Bioorg Med Chem Identification of novel uracil derivatives incorporating benzoic acid moieties as highly potent Dipeptidyl Peptidase-IV inhibitors.
2019 May Eur J Pharmacol The DPP-4 inhibitor saxagliptin ameliorates ox-LDL-induced endothelial dysfunction by regulating AP-1 and NF-κB.
2019 J Pharmacol Sci A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
2019 Jan J Biomed Sci Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension.
2019 Jan J Cardiovasc Pharmacol Ther The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients.
2018 Int J Endocrinol A Dipeptidyl Peptidase-4 Inhibitor Suppresses Macrophage Foam Cell Formation in Diabetic idbdbi Mice and Type 2 Diabetes Patients.
2019 Jan Nephrol Dial Transplant Dipeptidyl peptidase-4 inhibitor teneligliptin accelerates recovery from cisplatin-induced acute kidney injury by attenuating inflammation and promoting tubular regeneration.